Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

NCT00143975 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Cytarabine
DRUG: Mitoxantrone
DRUG: Gemtuzumab Ozogamicin
DRUG: All-trans-Retinoid Acid

Sponsor

University of Ulm